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In urothelial bladder cancer (UBC), risk stratiﬁcation remains an important unmet need. Limitless self-renewal, governed by
TERT expression and telomerase activation, is crucial for cancer progression. Thus, telomerase activation through the interplay
of mutations (TERTpMut) and epigenetic alterations in the TERT promoter may provide further insight into UBC behavior. Here,
we investigated the combined effect of TERTpMut and the TERT Hypermethylated Oncological Region (THOR) status on
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telomerase activation and patient outcome in a UBC international cohort (n = 237). We veriﬁed that TERTpMut were frequent
(76.8%) and present in all stages and grades of UBC. Hypermethylation of THOR was associated with higher TERT expression
and higher-risk disease in nonmuscle invasive bladder cancers (NMIBC). TERTpMut alone predicted disease recurrence (HR:
3.18, 95%CI 1.84 to 5.51, p < 0.0001) but not progression in NMIBC. Combined THORhigh/TERTpMut increased the risk of
disease recurrence (HR 5.12, p < 0.0001) and progression (HR 3.92, p = 0.025). Increased THOR hypermethylation doubled the
risk of stage progression of both TERTpwt and TERTpMut NMIBC. These results highlight that both mechanisms are common and
coexist in bladder cancer and while TERTpMut is an early event in bladder carcinogenesis THOR hypermethylation is a dynamic
process that contributes to disease progression. While the absence of alterations comprises an extremely indolent phenotype,
the combined genetic and epigenetic alterations of TERT bring additional prognostic value in NMIBC and provide a novel
insight into telomere biology in cancer.
Introduction
Urothelial bladder cancer (UBC) poses signiﬁcant burden as it
is responsible for 123,051 deaths annually and at any given
time there are more than 500,000 UBC patients in the USA
alone.1,2 UBC is a remarkably heterogeneous disease, includ-
ing nonmuscle invasive (NMIBC) and muscle invasive disease
(MIBC). Pathological tumor stage and grade drive prognostic
predictions and ultimately, therapy recommendations. How-
ever, pathology alone is often insufﬁcient to predict individual
outcomes. Grade and stage are crude measures and many
patients are over- or undertreated as a result. Unlike other
cancer types, few molecular markers currently guide UBC
management.3,4
At diagnosis the majority of UBC (75%) are NMIBC (Ta,
T1), mostly low grade (LG). LG tumors are rarely lethal but
recur locally with variable and unpredictable rates.5,6 Muscle-
invasive bladder cancers (MIBC – T2, T3, T4), on the other
hand, almost universally high-grade (HG), can be lethal and
associated with worse clinical outcomes.5,6 A subset of
NMIBC are HG and destined to progress to life-threatening
MIBC. There is an unmet need to improve the prediction of
those patients with NMIBC at risk of progression to MIBC.
The stakes are high as NMIBC can be managed with conser-
vative therapy whereas MIBC requires either the removal of
the bladder (cystectomy) or chemo-radiation.7
Telomerase, the enzyme complex responsible for maintain-
ing telomere length and genome integrity is responsible for
cellular immortalization (a hallmark of cancer).8–11 Telome-
rase activity is upregulated in 85–90% of all cancers.12,13
Mutations in the promoter of the catalytic subunit of the
enzyme, termed telomerase reverse transcriptase (TERT) are
frequently observed in several cancers and drive telomere
maintenance.14–16 In UBC, TERT promoter mutations (C to T
transitions at chr5:1,295,228 and chr5:1,295,250) are more
common than any other genetic alterations and can lead to
increased TERT expression and telomerase activity.17–20
Importantly, TERT promoter mutations are associated with
worse clinical outcome in most studies further highlighting
the role of telomerase activation in tumor progression and
recurrence.18–27 Noteworthy, not all TERTpMut tumors display
telomerase activation and non-TERTpMut UBC may express
TERT suggesting that the presence of additional mechanisms
are necessary for telomerase activation in UBC.28
Our group and others have identiﬁed a parallel epigenetic
control of telomerase activation in cancer. Speciﬁcally, a
region located upstream of the core mutation area, within the
TERT promoter, termed THOR (TERT Hypermethylated
Oncological Region) is hypermethylated in many TERT-
expressing cancers, is associated with telomerase activation
and predicts clinical outcomes in multiple tumor types.14,29,30
We therefore hypothesized that dual mechanisms activate
telomerase in UBC. Here, we studied the interaction and con-
tribution of both genetic (TERTpMut) and epigenetic (THOR)
TERT promoter alterations to telomerase activation and prog-
nosis in UBC, using a multi-institutional cohort.
Material and Methods
Open access data
The Cancer Genome Atlas (TCGA) Research Network
(http://cancergenome.nih.gov) database for UBC was ana-
lyzed. A single, probe located within THOR (cg11625005)
was used for methylation analysis (Illumina Inﬁnium 450 k
array). TERT expression data were evaluated from the gene
What’s new?
Telomerase reverse transcriptase (TERT) activation is central to cancer cell immortalization. It acts, however, through relatively
unknown mechanisms. In urothelial bladder cancer (UBC) in particular, TERT activation can occur in the presence or absence of
mutation, raising questions about alternative activation mechanisms. Our study shows that hypermethylation of the TERT
promoter (THOR) plays a key part in UBC, being a dynamic and progressive process, with hypermethylation levels increasing
with bladder cancer severity. Moreover, both hypermethylation and TERT promoter mutation contributed to increased
telomerase expression. The ﬁndings provide insight into telomere biology in UBC and may be applicable to other tumors.
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expression dataset (polyA+IlluminaHiSeq) (details in Sup-
porting Information).
Patients
Patients’ selection and pathological characteristics are pre-
sented in Supporting Information Table S1. All patients
underwent surgery (either transurethral bladder resection or
radical cystectomy) and followed for a median period of
107.4 months (IQR: 32.4–266.8 months). 331 bladder tissue
samples, from 331 patients (237 UBC and 94 normal urothe-
lium) were collected and analyzed for THOR methylation,
TERT promoter mutations and a subgroup for hTERT expres-
sion. Survival data was collected for the 237 patients with
UBC. On 10 of these patients, an additional tumor at
recurrence/progression was analyzed.
Molecular analysis of the TERT promoter
Sanger Sequencing was used to determined TERT promoter
mutation status. Samples were considered mutant (TERTpMut)
if any of the mutations (1,295,228 G > A or 1,295,250 G > A)
were present (Supporting Information Table S2). Quantitative
sodium bisulﬁte pyrosequencing was performed for THOR as
previously described.30 TERT expression was performed with
the QX200 Droplet Digital PCR system (see Supporting
Information for details).
Statistical analysis
SAS version 9.4 was used for statistical analyses. THOR was
initially evaluated as a continuous value to determine its asso-
ciation with normal and malignant urothelial bladder tissue
and to further interrogate its association with stage, grade and
high and low risk disease. For the prognostic model we
dichotomized into high- and low-THOR-methylation groups
by receiver operating characteristic (ROC) analysis. Clinical
outcomes for the TERT promoter mutations and THOR
methylation were determined by Kaplan–Meier Survival
curves. Cox Proportional Hazards (CPH) models were used
to assess univariate and multivariate signiﬁcance (details
Supporting Information).
Results
TERT promoter mutations are early and frequent events
in UBC
TERT promoter mutations (TERTpMut) were highly prevalent
(76.8%, n = 182). The predominant alteration was g.1,295,228
C > T which accounted for 90.1% of all mutations. No muta-
tions were found in normal urothelium (Table 1).
TERTpMut were identiﬁed in all stages and grades of UBC
[detected in 69.3% of NMIBC (n = 135/199) and 73.4% of
low-grade lesions]. TERTpMut were identiﬁed in all metastatic
(tumor positive) pelvic lymph nodes as well as in their corre-
sponding primary tumor. Interestingly, TERTpMut were also
identiﬁed in some tumor negative lymph nodes (Supporting
Information Table S3).
Consistent with previous studies, some of these TERTpMut
UBC did not exhibit high TERT expression even when com-
pared to UBC with a wild type promoter (TERTpWt) (Sup-
porting Information Fig. S1A, S1C).18
These data support an early oncogenic role of TERTpMut
and the possibility that other mechanisms may also upregulate
TERT expression in UBC.
THOR hypermethylation is a dynamic process in UBC
tumorigenesis
In order to evaluate the extent of THOR methylation and its
effect on TERT expression in UBC we analyzed a representa-
tive CG site within THOR (cg11625005) in a cohort of MIBC
from the TCGA (n = 433). When compared to normal
urothelium, MIBC had signiﬁcantly higher methylation at
THOR and higher TERT mRNA levels (Supporting
Table 1. Summary of TERT promoter methylation (THOR) and TERT
promoter mutation status
THOR Methylation
THORlow 110 46.4%
THORhigh 127 53.6%
Stage THORlow THORhigh
Ta 45 43.7% 58 56.3%
T1 49 51% 47 49%
 T2 16 42.1% 22 57.9%
Total 110 46.4% 127 53.6%
Grade THORlow THORhigh
Low Grade 76 56.3% 59 43.5%
High Grade 28 27.5% 74 72.5%
Total 104 43.9% 133 56.1%
THOR Methylation
TERTpMutStatus
TERTpWt 55 23.2%
TERTpMut 182 76.8%
TERT promoter mutations (per mutation)
C228T 164 90.1%
C250T 18 9.9%
C228T/C250T 0 0%
Total 182 100%
THOR Methylation Wt (n/%) Mutant (n/%)
Ta 28 27.2% 75 72.8%
T1 23 24.0% 73 76.0%
 T2 4 10.5% 34 89.5%
Total 55 23.2% 182 76.8%
THOR Methylation Wt (n/%) Mutant (n/%)
Low Grade 36 26.7% 99 73.4%
High Grade 19 18.6% 83 81.4%
Total 55 23.2% 182 76.8%
THORlow = THOR hypomethylated; THORhigh = THOR hypermethylated;
TERTpMutStatus = TERT promoter mutation status; TERTpMut = TERT
promoter mutation; TERTpWt = TERT promoter wild type.
Frequency of TERT promoter mutations (wild type and mutant) and THOR
methylation (hypomethylated and hypermethylated) according to stage
and grade disease.
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Information Fig. S2A, p < 0.0001; Supporting Information Fig.
S2B, p < 0.0001). THOR hypermethylated (THORhigh) was
associated with considerably higher TERT mRNA levels in
malignant tissue (Supporting Information Fig. S2C,
p < 0.0001) further supporting the role of TERT promoter
methylation in TERT transcriptional activation.
To directly test this observation we assayed multiple repre-
sentative CG sites from THOR in normal and UBC samples
from our multi-institutional cohort. THOR was hypermethy-
lated (THORhigh) in 127 UBC (53.6%, Table 1) and signiﬁ-
cantly hypermethylated in tumors compared to benign
histology in nonmatched samples (Fig. 1a, p < 0.0001). Addi-
tionally, paired samples from the same surgical specimen
revealed that THOR methylation is 2 times higher in the tumor
region than the corresponding normal urothelium (Fig. 1b).
Since UBC are stratiﬁed by invasiveness (T stage) and cellu-
lar morphology (grade) as predictors of tumor progression, we
also tested THOR ability to distinguish stages and grades.
THOR methylation was signiﬁcantly higher in tumor tissue,
even when comparing superﬁcial lesions (Ta) with normal tissue
(Fig. 1c, p < 0.0001). THOR methylation levels are slightly
higher in T1 disease than in Ta (Fig. 1c, p = 0.049) but do not
reach the same signiﬁcant difference veriﬁed between normal
urothelium and Ta disease. Similarly, THOR methylation dem-
onstrated a progressive pattern from normal urothelium to low-
grade tumors and maintaining the same trend in high-grade
tumors (Fig. 1d). Clinically, THOR exhibited higher hyper-
methylation in high-risk (T1 and HG) when compared to low
risk tumors (Supporting Information Fig. S3, p = 0.034).31
To further explore the changes in THOR over time, we
assessed THOR methylation in UBC harvested from consecu-
tive surgeries (at both the time of the initial diagnosis and the
ﬁrst recurrence or progression). A signiﬁcant increase in
THOR methylation levels was observed in tumors with stage
progression (p = 0.018, mean increase fold of 1.76), but not in
nonprogressive ones (p = 0.88) suggesting that THOR is
hypermethylated in tumors harboring TERT promoter muta-
tions (Supporting Information Table S4).
Finally, analysis of TERT expression revealed that higher
levels of THOR methylation are related to higher levels of
expression (Supporting Information Fig. S1B, p = 0.049). The
highest TERT expression is observed when both alterations
(methylation and mutations) are present (Supporting
Information Fig. S1C).
Overall, these data suggest that THOR methylation
increases progressively during the earlier stages of UBC and
Figure 1. THOR methylation in urothelial bladder cancer. (a) THOR methylation status in normal urothelium and tumor tissue in the entire
cohort (****, p < 0.0001) (b) The ratio of tumor/normal tissue in paired samples from the same patient (n = 38). Note a mean of twofold
increase in THOR methylation status in the malignant tissue. (c) THOR methylation status in different tumor stages. (d) THOR methylation
status within tumor grades, low grade has signiﬁcantly higher THOR methylation than normal urothelium (****, p < 0.0001).
NS = nonsigniﬁcant. Error bars represent median and Interquartile range (IQR). [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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both TERT promoter mutations and hypermethylation con-
tribute to increased telomerase expression.
Prognostic value of TERT promoter alterations in NMIBC
As expected, in these selected cohorts, pathological grade was
predictive of progression (n = 199, p = 0.02) (Supporting
Information Fig. S4).
As THOR methylation increases with disease stage while
TERTpMut is an early event, we assessed the value of TERT
promoter alterations as markers of recurrence and disease
progression in NMIBC.
Consistent with previous reports, patients harboring
TERTpMut had a signiﬁcantly higher risk of recurrence (HR:
3.18, 95% CI 1.8–5.5; p < 0.0001; Table 2) with signiﬁcantly
decreased median disease free survival (Log rank p < 0.0001;
Fig. 2a).17,18,25 However, TERTpMut status did not reach statis-
tical signiﬁcance with respect to the risk of progression to
invasive disease (p = 0.052) (Fig. 2b, Table 2).17,18
As for TERTpMut, THORhigh NMIBC recurred more fre-
quently (HR: 1.5, 95% CI 1.02–2.20; p = 0.03; Table 2), with
decreased median disease-free survival (76 months vs.
31.7 months) (Log rank p = 0.034; Fig. 2c). Also, THORhigh
did not reach signiﬁcance for the risk of progression (Log
rank p = 0.059; Fig. 2d, Table 2) in NMIBC.
Combined TERT promoter alterations predict disease
progression in NMIBC
We then analyzed the combined prognostic impact of both
TERT promoter alterations in NMIBC. We ﬁrst evaluated the
association of TERT promoter alterations and clinical out-
comes according to grade and stage of NMIBC. THORhigh/
TERTp
Mut was the most common phenotype in NMIBC which
recurred or progressed independently of stage (Supporting
Information Figs.S5 and S6). The absence of any alteration
(THORlow/TERTp
Wt) was associated with a more indolent
phenotype even in HG NMIBC (Supporting Information
Fig. S6).
Concomitant THOR hypermethylation and mutations
(THORhigh/TERTp
Mut) were associated with increased risk of
disease recurrence (HR: 5.12; 95% CI 2.23–11.32, Table 2)
with less than 30% disease free survival (DFS) at 10 years. In
contrast, the absence of both alterations (THORlow/TERTp
Wt)
was associated with 80% DFS at 10 years (Fig. 3a, Log rank
p < 0.0001). The presence of either TERT promoter alterations
(TERTpMut or THORhigh) increased the risk of disease recur-
rence with a worse disease free survival (30.8% and 45% at
10 years, respectively; Fig. 3a).
The presence of either TERT promoter alterations con-
ferred a 4.53-fold increased risk of recurrence (95% CI
2.05–10.01; p = 0.0002) but not for progression (p = 0.14).
Combined THORhigh /TERTp
Mut was a risk factor for both
recurrence (HR: 5.4; CI 95% 2.42–12.04; p < 0.0001) and
progression (HR: 4.01; CI 95% 1.19–13.5; p = 0.024; Table 2).
Furthermore, THORlow/TERTp
Wt NMIBC patients had a
91.4% progression free survival (PFS) at 10 years of follow-up,
signiﬁcantly better than THORhigh/TERTp
Mut (66.4% PFS; Log
rank p = 0.019; Fig. 3b). When adjusting for stage (T1 vs. Ta),
grade (HG vs. LG), gender and age, THORhigh/TERTp
Mut also
displays a trend toward signiﬁcance (HR: 3.32, CI 95%
0.99–11.16; p = 0.05) (Supporting Information Table S5).
We then tested the effect of continuous increase in THOR
methylation to enhance the predictive ability of disease pro-
gression in NMIBC, adjusting for TERT promoter mutations
status. THOR levels affected disease progression in both
TERTpMut and TERTpWt phenotypes. Increased THOR meth-
ylation from 10% (normal) to 50%, more than doubled the
risk of disease progression independently of TERT promoter
mutation status (Fig. 4).
Table 2. Univariate Cox proportional hazards regression analysis of time for disease recurrence and disease progression in NMIBC (n = 199)
Disease Recurrence Disease Progression
HR 95% CI Chi Sq P HR 95% CI Chi Sq P
TERTpMutationStatus
TERTpWt (n = 51) Ref Ref
TERTpMut (n = 148) 3.18 1.8 to 5.5 17.16 <0.0001 2.36 0.99 to 5.60 3.82 0.052
THORMethy
THORlow (n = 105) Ref Ref
THORhigh (n = 94) 1.50 1.0 to 2.2 4.37 0.03 1.81 0.97 to 3.35 3.52 0.057
THORMethy/TERTpMutStatus
THORlow/TERTpWild (n = 35) Ref Ref
THORlow/TERTpMut + THORhigh/TERTpWild
(n = 85)
4.53 2.0 to 10 13.86 0.0002 2.64 0.77 to 9.1 2.38 0.123
THORhigh/TERTpMut
(n = 79)
5.12 2.3 to 11.3 16.33 <0.0001 3.92 1.2 to 13.0 4.97 0.025
HR = Hazard ratio; CI: confidence interval; Chi Sq = Chi Squared.
TERTpMutStatus = TERT promoter mutation status (for the studied mutations); TERTpWt = TERT promoter wild type; TERTpMut = TERT promoter mutant;
THORMethy = THOR methylation status; THORhigh = THOR hypermethylated; THORlow = THOR hypomethylated.
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Discussion
Our study is the ﬁrst to assess concomitant TERT promoter
alterations in UBC. Our results suggest a temporal and cooper-
ative association between TERT promoter mutations and meth-
ylation, impacting telomere biology and clinical outcomes.
TERT expression is upregulated in 85–90% of tumors via
multiple molecular mechanisms including somatic mutations,
TERT ampliﬁcations, TERT structural variants and epigenetic
modiﬁcations through TERT promoter methylation.14 Our
data reveal that 76.8% of UBC cancers harbor TERTpMut and
53.6% have THORhigh, and 24.6% (n = 49/199) of LG NMIBC
acquired both alterations. The kinetics and interaction of these
alterations in UBC, and the resulting effect on TERT expres-
sion are still unknown and important to decipher.
Figure 2. Survival estimates for patients with NMIBC stratiﬁed by TERT promoter alterations. (a) Disease free and (b) progression free survival
for patients with NMIBC stratiﬁed by TERT promoter mutation status. (c) Disease free and (d) progression free survival for patients with NMIBC
stratiﬁed by TERT promoter methylation status. THORlow = THOR hypomethylated, THORhigh = THOR hypermethylated. TERTpWt = TERT promoter
wild type (for the two studied mutations); TERTpMut = TERT promoter mutant. Yellow = TERTpWt and THORlow; Blue = TERTpMut and THORhigh.
Figure 3. Survival analysis of combined TERT promoter alterations in patients with NMIBC. Kaplan–Meier analysis for (a) disease free and (b)
progression free survival stratiﬁed by combined TERT promoter mutations and THOR methylation status in nonmuscle invasive bladder cancer
patients. THORlow/TERTpWt = blue; THORlow/TERTpMut = light red; THORhigh/TERTpWt = green; THORhigh/TERTpMut = dark red.
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The observation that TERTpMut are found ubiquitously
across all stages and grades of UBC, even in low stage and grade
lesions with low TERT expression, suggests that TERTpMut is an
early event necessary but insufﬁcient by itself to drive disease
progression. In fact other studies also veriﬁed that TERT
promoter mutant UBC might express low mRNA levels.18 Simi-
lar data exist in other tumors where TERT promoter mutations
are common. For example, in gliomas, TERTpMut are detected
in lower grade lesions where TERT expression and self-renewal
are low.32,33
TERTpMut is necessary but not sufﬁcient to maintain
telomere length or telomerase upregulation.28 In TERTpMut
tumors additional alterations are likely required to upregulate
telomerase and promote tumor progression.
We previously showed that THOR hypermethylation is a
dynamic process during gliomagenesis and prostate cancer
progression.29,30 In UBC, TERTpMut is an early event while
THOR hypermethylation is associated with disease progres-
sion and increased TERT expression. This pattern has been
observed in other cancer types.14,29,30
A weakness of the WHO 2004/2016 pathological classiﬁca-
tion of NMIBC is that it gives almost no prognostic informa-
tion in T1 patients as nearly all are classiﬁed as HG.34 In our
study, TERT promoter alterations add signiﬁcant value as
prognostic biomarkers. For example, T1 THORlow/TERTpWt
tumors, including HG lesions, carry a risk of progression of
less than 10%, in sharp contrast with the 52% of progression
for THORhigh/TERTpMut. If conﬁrmed in prospective studies,
this may help guide management when choosing conservative
vs. aggressive therapy for these patients. Given the high recur-
rence rate in NMIBC, the identiﬁcation of patients with very
low potential for disease recurrence and progression might
change the costly and invasive follow-up protocols in favor of
individualized strategies.
In contrast, THORhigh/TERTpMut signiﬁcantly increased
the chance of NMIBC recurrence and is a risk factor for dis-
ease progression across stages and grades. Furthermore, for
the different TERT promoter mutation status, continuous
THOR hypermethylation increases the risk of disease progres-
sion, reinforcing the dynamic and crucial role of THOR meth-
ylation in bladder cancer tumorigenesis. Further supporting
the role of THOR methylation, tumors exhibited higher
THOR methylation at the time of stage progression.
Together, our ﬁndings support the hypothesis that TERTpMut
are early triggers in tumorigenesis which require cooperation
with other events including THOR hypermethylation to ensure
telomerase activation, immortality and disease progression.
The exact mechanism of telomerase activation by promoter
hypermethylation remains under investigation. One possible
explanation is that methylation leads to three-dimensional
changes in local chromatin architecture resulting in increased
transcription.35 Alternatively, methylation of this distal part of
the promoter might also prevent the binding of transcriptional
repressors, which in turn enables TERT expression.36 These
Figure 4. Estimated probability of disease progression based on THOR methylation levels. Risk of progression is estimated by any TERT
promoter mutation status (wild type or mutant) as a result of increased THOR methylation. Red-TERT promoter mutant NMIBC, Black-TERTpWt
NMIBC.
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mechanisms ought to be explored further as they may result
in the development of novel targeted therapies. Demethylating
agents have shown some encouraging results in cancers where
THOR is hypermethylated, and may have a role in decreasing
the risk of progression of NMIBC.37
Our study has limitations due to its retrospective nature,
patient selection, absence of centralized pathology review
(although we chose speciﬁcally the HG vs. LG 2004/16 WHO
classiﬁcation less prone to inter-observer variability).34 Impor-
tantly, one should interpret the univariate and multivariate
analysis with caution as Ta ant T1 tumors are treated differ-
ently. Furthermore, since large numbers of tumors are neces-
sary for survival analysis in NMIBC, in our multivariate
analysis THORHigh/TERTpMut only showed a trend toward
signiﬁcance as a risk factor for disease progression. Future
studies with higher number of NMIBC tumors are needed to
empower and statically validate our preliminary ﬁndings. Sim-
ilarly, the limited numbers of patients with muscle invasive
disease prevented a meaningful evaluation of this subgroup.
However, since most of the prognostic role of TERT activation
through THOR hypermethylation is observed during early
stages of tumor development in multiple cancers, and NMIBC
was the focus of the present study, our results suggest a simi-
lar process in UBC carcinogenesis.
In summary, our study further supports the role of epige-
netic control of the TERT promoter by THOR hypermethyla-
tion as a dynamic and progressive process in carcinogenesis,
including UBC. The concomitant evaluation of TERT pro-
moter mutation-methylation in NMIBC has identiﬁed a group
with more indolent outcome, independently from grade or
stage. Additional prospective studies should conﬁrm that
THORlow/TERTpWt tumors have a reduced risk of recurrence
and progression to invasive disease. This should be explored
in other tumor types known for harboring TERT promoter
mutations and telomerase upregulation. A better understand-
ing of the interplay between these two tumor-speciﬁc TERT
activating mechanisms might improve clinical management in
UBC and other TERT-dependent cancers.
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